Products
Sofituzumab Biosimilar Antibody-Drug Conjugate (MUC16) for Research
Pre-Made Sofituzumab biosimilar, Whole mAb ADC, Anti-MUC16 Antibody: Anti-CA125 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sofituzumab vedotin (INN; development code DMUC5754A) is a monoclonal antibody designed for the treatment of ovarian cancer. This drug was developed by Genentech/Roche.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-526-1mg | 1mg | 4635 |
| GMP-Bios-ab-526-10mg | 10mg | |
| GMP-Bios-ab-526-100mg | 100mg | |
| GMP-Bios-ab-526-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sofituzumab biosimilar, Whole mAb ADC, Anti-MUC16 Antibody: Anti-CA125 therapeutic antibody |
| INN Name | Sofituzumab |
| Target | MUC16 |
| Format | Whole mAb ADC |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer |
| Development Tech | na |
About target - MUC16
1. Protein Mucin-16
2. Gene MUC16
3. Organism Homo sapiens (Human)
Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Miscellaneous
Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.
